Diabetes

In part 2 of our interview with Sandra Leal, PharmD, MPH, she explored the ADA Standards of Care and how pharmacists are positioned to assist in interoperable diabetes management.

Older adults with type 2 diabetes often juggle 5 or more different prescriptions.

This regulatory milestone establishes inhaled insulin as the first and only noninjectable mealtime insulin option for children and adolescents.

Real-world data show GLP-1 drugs in type 1 diabetes cut heart and kidney risks, support weight loss, and appear safe with insulin adjustments.

As diabetes rises to be one of the most prominent chronic diseases globally, pharmacists have reached out as key resources for preventing and managing its complications.

Meta-analysis shows empagliflozin is superior to sitagliptin with metformin for glycemic control.

The FDA seeks to bar bulk compounding of semaglutide, tirzepatide, and liraglutide, spotlighting risks in online glucagon-like peptide-1 copies.

In part 2, Staci-Marie Norman, PharmD, CDCES, FAPhA, and Susan Cornell, PharmD, CDCES, FAPhA, FADCES, discuss the pharmacist’s ability to meander a booming medication class in GLP-1s.

New research shows inflammation and diabetes raise preterm birth risk, suggesting C-reactive protein testing.

The weight-loss and diabetes drug will now be available via Amazon Pharmacy for same-day delivery or in-person kiosk pickup.

Episode 10 explores recent guideline changes in clinicians’ management of dyslipidemia, highlighting much more than a few updated recommendations.

Exploring clinical prioritization and macroeconomic investment, researchers examine the link between disease and economic burden of diabetes.

GLP-1 prescriptions surge to nearly 8% of fills, fueled by weight-loss demand.

FDA clears Langlara interchangeable insulin glargine, enabling pharmacy substitution for Lantus and widening affordable basal insulin access.

Researchers find Reddit posts provides a look at the real-world adverse effects of glucagon-like peptide-1 receptor agonists.

The 2026 guidance emphasizes that selecting newer and innovative agents should occur early, dependent on comorbidities of the patient.

FDA expands Tzield use to age 1 year to delay stage 3 type 1 diabetes, enabling earlier immune intervention.

A long-term trial shows oral orforglipron boosts A1C and weight loss with reassuring cardiovascular safety and simpler dosing for type 2 diabetes.

Pharmacists optimize insulin therapy, including basal and bolus dosing, missed-dose tips, continuous glucose monitoring insights, and affordability.

Non-high-density lipoprotein cholesterol matters in type 2 diabetes care and can be managed with statins, combination therapy, and omega‑3s.

Tentative FDA nod for generic semaglutide signals more glucagon-like peptide-1 access, easing pharmacy hurdles and curbing risky compounded alternatives.

Meta-analysis shows CGM lowers HbA1c and hypoglycemia in insulin-treated type 2 diabetes, while pharmacists tackle training, costs, and skin issues.

Researchers assess medication adherence across initial combination therapy users during their first year of type 2 diabetes treatment.

Episode 9 dives into the landscape of obesity pharmacotherapy, detailing current therapies, clinical updates, future pipelines, and more.

Community pharmacists weave brief lifestyle coaching and point-of-care testing into medication management, improving diabetes and hypertension outcomes.